Celldex Therapeutics Inc

Most Recent

  • uploads///Part  Graph
    Company & Industry Overviews

    Celldex Rose on Phase 2 Melanoma Data

    On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    iShares Nasdaq Biotechnology ETF (IBB) Had Strong Start to April

    Celldex Therapeutics (CLDX) was the top performer among IBB holdings, rising 10.6% on April 4. The other top performers include Synergy Pharmaceuticals (SGYP) and Sage Therapeutics (SAGE)

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    XBI Tops Biotech ETF’s for the Week Ended November 27

    Sarepta Therapeutics closed at $37.4 and was trading 15.2% above the 100-day moving average price of $32.5. It has a weight of 0.8% in XBI.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Immunogen Topped the Small-Cap Stocks with High Volumes

    Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Celldex Leads the Small-Cap Stocks in IBB

    Celldex rose by 12.3%. This is the second consecutive trading session the stock gained after it presented varlilumab data at the SITC Annual Meeting 2015.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.